CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers China Medical System Holdings Limited Aug 19, 2025 16:00 JST Read More
UNFPA and NEC Collaborate to Build Beneficiary Information Management and e-Voucher System NEC Corporation Aug 18, 2025 13:38 HKT/SGT Read More
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China Eisai Aug 18, 2025 08:11 HKT/SGT Read More
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC Eisai Jul 31, 2025 08:30 HKT/SGT Read More
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease Eisai Jul 31, 2025 08:20 HKT/SGT Read More
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 Eisai Jul 31, 2025 08:10 HKT/SGT Read More
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma Eisai Jul 29, 2025 08:01 HKT/SGT Read More
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China China Medical System Holdings Limited Jul 29, 2025 05:00 JST Read More
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China Essex Bio-Technology Limited Jul 25, 2025 11:52 JST Read More
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million Everest Medicines Limited Jul 25, 2025 11:01 JST Read More
Launch of Beova(R) Tablets in Thailand for Overactive Bladder Eisai Jul 23, 2025 09:07 HKT/SGT Read More
Crown Bioscience San Diego Achieves CLIA Certification to Enhance Clinical Trial Support Crown Bioscience Jul 23, 2025 09:00 HKT/SGT Read More
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025 Eisai Jul 22, 2025 10:56 HKT/SGT Read More
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab Eisai Jul 16, 2025 13:50 HKT/SGT Read More
エーザイ、CDP から「サプライヤー・エンゲージメント評価」において最高評価である「サプライヤー・エンゲージメント・リーダー」に選定 Eisai Jul 08, 2025 09:00 JST Read More
Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis Hua Medicine Jun 23, 2025 12:05 HKT/SGT Read More
